Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 27;7(52):85937-85947.
doi: 10.18632/oncotarget.13262.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Sarah Bertoli  1   2   3 , Arthur Sterin  4 , Suzanne Tavitian  1 , Lucie Oberic  1 , Loïc Ysebaert  1   2   3 , Reda Bouabdallah  4 , François Vergez  3   5 , Audrey Sarry  1 , Emilie Bérard  6   7 , Françoise Huguet  1 , Guy Laurent  1   2 , Thomas Prébet  4   8 , Norbert Vey  4   8   9 , Christian Récher  1   2   3
Affiliations

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Sarah Bertoli et al. Oncotarget. .

Abstract

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.

Keywords: chronic lymphocytic leukemia; leukemia; lymphoma; second cancer; therapy-related acute myeloid leukemia.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest related to this study.

Figures

Figure 1
Figure 1. Overall survival after intensive chemotherapy according to AML type
See this image and copyright information in PMC

References

    1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302. - PubMed
    1. Swerdlow SH. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. pp. 109–138.
    1. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med. 2005;352:1529–38. - PubMed
    1. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia: report of four cases possibly related to melphalan. N Engl J Med. 1970;283:1121–5. - PubMed
    1. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med. 2005;352:1591–4. - PubMed